{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:56:44Z","timestamp":1777877804052,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:p>\n                    To investigate the clinical characteristics and treatment efficacy in advanced lung cancer patients with adrenal insufficiency (AI) induced by immune checkpoint inhibitors (ICIs). A retrospective study was conducted on advanced lung cancer patients who developed AI following ICI treatment at Lishui Central Hospital between January 2019 and November 2024. Patients from both the Oncology and Respiratory &amp; Critical Care Departments were included. Clinical data, laboratory results, imaging findings, and the association between secondary AI onset and treatment efficacy were analyzed. A total of 35 patients were included in the study. Of these, 2 patients (5.7%) achieved complete response, 8 patients (22.9%) achieved partial response, 24 patients (68.6%) had stable disease and 1 case (2.9%) showed progressive disease. The overall response rate was 31.8%, with a duration of response of 100%. The median progression-free survival (PFS) for all patients was 10.9 months (95% CI: 6.959\u201314.841). PFS significantly differed between patients who developed secondary AI within 3 months of ICI initiation and those who developed it later (8.0 months vs 11.0 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.033). Secondary AI is a rare but significant immune-related adverse event associated with ICIs. Advanced lung cancer patients with secondary AI tend to exhibit a more favorable response to immunotherapy. The timing of AI onset appears to critically influence ICI efficacy, with late-onset AI (&gt;3 months) correlating with markedly prolonged PFS \u2013 a novel prognostic association not previously reported.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043983","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T21:01:35Z","timestamp":1756846895000},"page":"e43983","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and immunotherapy efficacy in advanced lung cancer patients with immune checkpoint inhibitor-related adrenal insufficiency"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1164-946X","authenticated-orcid":false,"given":"Lu","family":"Xu","sequence":"first","affiliation":[{"name":"Dr. Neher\u2019s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Yao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2951-8108","authenticated-orcid":false,"given":"Vincent Kam Wai","family":"Wong","sequence":"additional","affiliation":[{"name":"Dr. Neher\u2019s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260430","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mor tality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbcan.2019.02.004","article-title":"Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1\/PD-L1 therapy with thoracic radiotherapy.","volume":"1871","author":"Li","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R3-20260430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20260430","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"R5-20260430","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency.","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"102454","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors.","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.","volume":"50","author":"Martella","year":"2023","journal-title":"Semin Oncol"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors.","volume":"36","author":"Iwama","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"R11-20260430","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2217\/fon-2018-0868","article-title":"Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.","volume":"15","author":"Tartarone","year":"2019","journal-title":"Future Oncol"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","article-title":"Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"16","author":"Petrelli","year":"2021","journal-title":"Target Oncol"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/1759-7714.14761","article-title":"Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.","volume":"14","author":"Kurokawa","year":"2023","journal-title":"Thorac Cancer"},{"key":"R15-20260430","doi-asserted-by":"crossref","first-page":"111337","DOI":"10.1016\/j.intimp.2023.111337","article-title":"Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: a retrospective cohort study.","volume":"127","author":"Cai","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"101787","DOI":"10.1016\/j.tranon.2023.101787","article-title":"Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency.","volume":"38","author":"Xiang","year":"2023","journal-title":"Transl Oncol"},{"key":"R17-20260430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients.","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors.","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline.","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"720769","DOI":"10.3389\/fendo.2021.720769","article-title":"Latent adrenal insufficiency: from concept to diagnosis.","volume":"12","author":"Younes","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41598-022-05400-x","article-title":"Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.","volume":"12","author":"Takayasu","year":"2022","journal-title":"Sci Rep"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"e002535","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.","volume":"9","author":"Tarhini","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R24-20260430","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3390\/cancers13102365","article-title":"Investigating the impact of immune-related adverse events, glucocorticoid use and immunotherapy interruption on long-term survival outcomes.","volume":"13","author":"Bruy\u00e8re","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"e0200633","DOI":"10.1371\/journal.pone.0200633","article-title":"Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: an analysis of Iranian patients.","volume":"13","author":"Fathi","year":"2018","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:24Z","timestamp":1777590144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":25,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043983","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2024-12-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}